IMTX · NASDAQ
Immatics N.V.
$7.31 -0.24 (-3.12%)
Company overview
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in…
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $1.1B
- Employees
- 554
- Headquarters
- Tübingen
- Website
- immatics.com
- CEO
- Harpreet Singh
- Listed
- December 12, 2018
- P/E
- -4.27
- Dividend yield
- 0.00%
Company financials
- Revenue
- $37.3M
- Gross profit
- $37.3M
- Operating income
- -$213M
- EBITDA
- -$202M
- Net income
- -$214M
- EPS
- -$1.71
- Total assets
- $544M
- Total debt
- $15.1M
- Gross margin
- 100.00%
- Net margin
- -574.86%
- Earnings yield
- -23.39%
IMTX
1D
NASDAQ
O7.46H7.50L7.25C7.31-0.24 (-3.12%)Vol215.23K